BETHESDA, Md., Sept. 12, 2023 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax personalized immune therapies for solid tumor cancers, announces that Dr. Linda Liau, MD, PhD, MBA has joined the Company's Scientific Advisory Board (SAB).
Dr. Liau served as the Principal Investigator of the Phase 3 trial of DCVax-L for treatment of glioblastoma. She is Chair of the Department of Neurosurgery at UCLA, Professor and Director of the UCLA Brain Tumor Program. Dr. Liau is the former Editor-in-Chief of the Journal of Neuro-Oncology. She is the Director of the UCLA Brain Cancer SPORE (Specialized Program of Research Excellence). She is an elected member of the National Academy of Medicine.
The longstanding members of the Company's Scientific Advisory Board include Dr. Samir Khleif, Dr. Jerome Galon and Dr. John Smyth, and also included Dr. Mac Cheever for many years until his passing.
Linda Powers, NWBio CEO, commented: "We are delighted to have Dr. Liau join our existing distinguished SAB. Her experience as a leader in the neuro-oncology field, her decades of research and knowledge of both brain cancer biology and immunotherapies, and her extensive experience with DCVax-L as the Principal Investigator of the Phase 3 trial, will be invaluable as we work together on DCVax-L approval and on future clinical programs building on that."
About Northwest Biotherapeutics
Northwest Biotherapeutics is a biotechnology company focused on developing personalized immunotherapy products designed to treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies, and on a cost-effective basis, in both North America and Europe. The Company has a broad platform technology for DCVax dendritic cell-based vaccines. The Company's lead program is a 331-patient Phase III trial of DCVax-L for newly diagnosed Glioblastoma multiforme (GBM). GBM is the most aggressive and lethal form of brain cancer, and is an "orphan disease." This Phase III trial has been completed, and the results have been presented in scientific meetings and published in JAMA Oncology. The Company has also developed DCVax-Direct for inoperable solid tumor cancers. It has completed a 40-patient Phase I trial and, as resources permit, plans to pursue Phase II trials. The Company previously conducted a Phase I/II trial with DCVax-L for advanced ovarian cancer together with the University of Pennsylvania.
馬里蘭州貝塞斯達,2023年9月12日 /PRNewswire/ — 開發DCVax實體瘤個性化免疫療法的生物技術公司Northerwest Biotherapeutics公司(OTCQB:NWBO)(“NW Bio”)宣佈,醫學博士、工商管理碩士Linda Liau博士已加入該公司的科學顧問委員會(SAB)。
Liau博士曾擔任dcVax-L治療膠質母細胞瘤的3期試驗的首席研究員。她是加州大學洛杉磯分校神經外科系主任,加州大學洛杉磯分校腦腫瘤項目教授兼主任。Liau博士是該雜誌的前主編 神經腫瘤學雜誌。 她是加州大學洛杉磯分校腦癌SPORE(卓越研究專業項目)的主任。她當選爲美國國家醫學院院士。
公司科學顧問委員會的長期成員包括薩米爾·赫萊夫博士、傑羅姆·加隆博士和約翰·史密斯博士,還包括麥克·切弗博士在他去世之前多年。
NWBio首席執行官琳達·鮑爾斯評論說:“我們很高興Liau博士加入我們現有的傑出SAB。她作爲神經腫瘤學領域領導者的經驗、她數十年的腦癌生物學和免疫療法研究和知識,以及她作爲3期試驗首席研究員在dcVax-L方面的豐富經驗,將是非常寶貴的,因爲我們共同努力獲得dcVax-L的批准以及在此基礎上開展未來的臨床項目。”
關於Northwest Biotherapeutics
Northwest Biotherapeutics是一家生物技術公司,致力於在北美和歐洲開發個性化免疫療法產品,這些產品旨在比目前的治療方法更有效地治療癌症,不存在與化療相關的毒性,並且具有成本效益。該公司擁有基於dcVax樹突狀細胞的疫苗的廣泛平台技術。該公司的主導項目是一項針對新診斷的多形性膠質母細胞瘤(GBM)的dcVax-L的331名患者的III期試驗。GBM是最具侵略性和致命性的腦癌形式,是一種 “孤兒病”。該三期試驗已經完成,結果已在科學會議上公佈,並發表在《JAMA Oncology》上。該公司還開發了用於無法手術的實體瘤癌的DCVax-Direct。它已經完成了一項40名患者的一期試驗,並在資源允許的情況下計劃進行II期試驗。該公司此前曾與賓夕法尼亞大學一起使用dcVax-L進行了一項針對晚期卵巢癌的I/II期試驗。